President Trump met with pharma CEOs at the White House. After praising investments, a 'most favored nation' drug pricing ...

Federal appeals court overturns order blocking Avadel Pharmaceuticals from seeking FDA approval for Lumryz in idiopathic ...

A federal court handed the FDA and Eli Lilly a major win in a case challenging the end of the tirzepatide shortage.

Charles River Laboratories is set to start a strategic review and add four new board members after it settled on a ...

NewAmsterdam's obicetrapib reduced Lp(a) by 45% in Phase 3; C4 Therapeutics advances cemsidomide while dropping CFT1946; Vivo ...

Theriva Biologics' VCN-01 plus chemotherapy showed improved survival in pancreatic cancer patients vs. chemo alone in Phase ...

Los Angeles-based health system Cedars-Sinai is partnering with venture studio Redesign Health to build health tech startups ...

Novo Nordisk cuts 2025 revenue guidance due to higher than expected impact of US compound pharmacies producing semaglutide.

How did biopharma stocks react to Vinay Prasad’s appointment as director of one of the FDA's top jobs? Not well. Prasad, a ...

Vinay Prasad named to replace Peter Marks as head of FDA's Center for Biologics Evaluation and Research; discussion planned ...

Marea Therapeutics said on Wednesday that its lipid-lowering antibody cut both remnant cholesterol levels and remnant ...

Sarepta's stock falls 48% after FDA critic Vinay Prasad's appointment and poor Elevidys sales. Company cuts revenue forecast ...